




Circulation.
v 105, no. 11 (Mar. 19 2002)
General Collection
V 1 C1743
2002-03-26 13:49:41

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION





A



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

st page of the Table of Contents

■ Circulation Electronic Pages	1269	Actions of Ba ²⁺ on Human Forearm Blood Flow <i>Matthew Dawes, PhD, MRCP, et al</i>	1323
Fetus With Transposition of the Great Arteries★ <i>Mary T. Donofrio, MD</i>	e65–e66	Carotid Sinus Denervation in Humans <i>Arthur A.J. Smit, MD, PhD, et al</i>	1329
Cardiovascular News★		Prosthetic Heart Valves in Dialysis Patients <i>Charles A. Herzog, MD, et al</i>	1336
■ Clinician Update		Risk Stratification in Brugada Syndrome <i>Silvia G. Priori, MD, PhD, et al</i>	1342
Oral Anticoagulation for Acute Coronary Syndromes <i>Marc A. Brouwer, MD; Freek W.A. Verheugt, MD, PhD</i>	1270	Renal Effects of Adenosine Antagonist and Furosemide <i>Stephen S. Gottlieb, MD, et al</i>	1348
■ Brief Rapid Communications		Sympathetic Activity and Survival in ESRD <i>Carmine Zoccali, MD, et al</i>	1354
Treatment of Amiodarone-Induced Thyrotoxicosis <i>Faizel Osman, MB, MRCP, et al</i>	1275	■ Basic Science Reports	
Expression of IL-1 Receptor Antagonist by Plasmid DNA <i>Byung-Kwan Lim, MSc, et al</i>	1278	Fetal Atherogenesis and Aortic Gene Expression 	1360
Catheter-Based Endomyocardial Injection With MRI <i>Robert J. Lederman, MD, et al</i>	1282	Raloxifene Activates P13K/Akt Pathway <i>Tommaso Simoncini, MD, PhD, et al</i>	1368
■ Clinical Investigation and Reports		Propranolol and the Prevention of Heart Failure <i>Masahiro Doi, MD, et al</i>	1374
Trial of a Distal Embolic Protection Device 	1285	Cariporide and Losartan in Heart Failure <i>Jan P. Loennechen, MD, et al</i>	1380
Angiogenic Gene Therapy Trial in Patients With Stable Angina <i>Cindy L. Grines, MD, et al</i>	1291	■ Clinical Cardiology: New Frontiers	
Effect of Azithromycin on Endothelial Function <i>Nikhil Parchure, MRCP, et al</i>	1298	Diastolic Heart Failure <i>Michael R. Zile, MD; Dirk L. Brutsaert, MD</i>	1387
Ventricular Resynchronization <i>Leslie A. Saxon, MD, et al</i>	1304	■ Images in Cardiovascular Medicine	
Proinsulin and Coronary Heart Disease <i>Jee-Young Oh, MD, et al</i>	1311	Arrhythmogenic Right Ventricular Cardiomyopathy <i>J.A. McCrohon, MD, PhD, et al</i>	1394
Left Ventricular Remodeling, MI, and Heart Failure <i>Octavio A. Victal, MD, et al</i>	1317		

Circulation Electronic Pages

Images in Cardiovascular Medicine

- Premature Closure of the Foramen Ovale and Ductus Arteriosus in a Fetus With Transposition of the Great Arteries
Mary T. Donofrio, MD **Web Site Feature** ★ e65-e66


Clinician Update

- Oral Anticoagulation for Acute Coronary Syndromes
Marc A. Brouwer, MD; Freek W.A. Verheugt, MD, PhD 1270

Brief Rapid Communications

- Successful Treatment of Amiodarone-Induced Thyrotoxicosis
Faizel Osman, MB, MRCP; Jayne A. Franklyn, MD, PhD, FRCP; Michael C. Sheppard, PhD, FRCP; Michael D. Gammage, MD, FRCP 1275
- Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis
Byung-Kwan Lim, MSc; Seong-Choon Choe, MD, PhD; Jae-Ok Shin, BSc; Seong-Hyun Ho, MSc; Jong-Mook Kim, PhD; Seung-Shin Yu, PhD; Sunyoung Kim, PhD; Eun-Seok Jeon, MD, PhD 1278
- Catheter-Based Endomyocardial Injection With Real-Time Magnetic Resonance Imaging
Robert J. Lederman, MD; Michael A. Guttman, MSc; Dana C. Peters, PhD; Richard B. Thompson, PhD; Jonathan M. Sorger, BS; Alexander J. Dick, MD; Venkatesh K. Raman, MD; Elliot R. McVeigh, PhD 1282

Clinical Investigation and Reports*

- Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts
Donald S. Bain, MD; Dennis Wahr, MD; Barry George, MD; Martin B. Leon, MD; Joel Greenberg, MD; Donald E. Cutlip, MD; Unsal Kaya, MS; Jeffrey J. Popma, MD; Kalon K.L. Ho, MD, MSc; Richard E. Kuntz, MD, MSc; on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators 1285 
- Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris
Cindy L. Grines, MD; Matthew W. Watkins, MD; Greg Helmer, MD; William Penny, MD; Jeffrey Brinker, MD; Jonathan D. Marmur, MD; Andrew West, MD; Jeffery J. Rade, MD; Pran Marrott, MRCP, MSc; H. Kirk Hammond, MD; Robert L. Engler, MD 1291
- Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of *Chlamydia pneumoniae* Infection
Nikhil Parchure, MRCP; Emmanouil G. Zouridakis, MD; Juan Carlos Kaski, MD, DSc, FRCP 1298

*Supported in concept as prevention of cardiovascular disease by an unrestricted gift from Merck & Co. Pfizer provides an unrestricted gift for subscriptions to *Circulation* for Cardiology Fellows in training.

CIRCULATION (ISSN 0009-7322) is published weekly except combined the first two weeks in January and the last two weeks in December by Lippincott Williams & Wilkins at 16522 Hunters Green Parkway, Hagerstown, MD 21740. Business offices are located at 530 Walnut Street, Philadelphia, PA 19106-3621. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. Individuals may subscribe for their personal use at the following rates: \$206 for members of an American Heart Association scientific council and \$275 for nonmembers; international: \$353 for members of an American Heart Association scientific council and \$471 for nonmembers. Periodicals postage paid at Hagerstown, MD, and additional mailing offices. POSTMASTER: Send address changes to CIRCULATION, American Heart Association, Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740.

This material was copied
at the NLM and may be
subject US Copyright Laws

Effects of Long-Term Biventricular Stimulation for Resynchronization on Echocardiographic Measures of Remodeling <i>Leslie A. Saxon, MD; Teresa De Marco, MD; Jill Schafer, MS; Kanu Chatterjee, MB; Uday N. Kumar, MD; Elyse Foster, MD; for the VIGOR Congestive Heart Failure Investigators</i>	1304
Sex Differences in the Association Between Proinsulin and Intact Insulin With Coronary Heart Disease in Nondiabetic Older Adults: The Rancho Bernardo Study <i>Jee-Young Oh, MD; Elizabeth Barrett-Connor, MD; Nicole M. Wedick, MS</i>	1311
Left Ventricular Volume Reduction by Radiofrequency Heating of Chronic Myocardial Infarction in Patients With Congestive Heart Failure <i>Octavio A. Victal, MD; John R. Teerlink, MD; Efrain Gaxiola, MD; Arthur W. Wallace, MD, PhD; Sergio Najar, MD; David H. Camacho, MD; Augustin Gutierrez, MD; Gabriel Herrera, MD; Gustavo Zuniga, MD; Fausto Mercado-Rios, MD; Mark B. Ratcliffe, MD</i>	1317
Barium Reduces Resting Blood Flow and Inhibits Potassium-Induced Vasodilation in the Human Forearm <i>Matthew Dawes, PhD, MRCP; Christine Sieniawska, BSc, MPhil; Trevor Delves, PhD, CChem, EurClinChem, FRSC; Rahul Dwivedi, MRCP; Philip J. Chowienczyk, FRCP; James M. Ritter, MA, DPhil, FRCP</i>	1323
Long-Term Effects of Carotid Sinus Denervation on Arterial Blood Pressure in Humans <i>Arthur A.J. Smit, MD, PhD; Henri J.L.M. Timmers, MD; Wouter Wieling, MD, PhD; Mariette Wagenaar, MD; Henri A.M. Marres, MD, PhD; Jacques W.M. Lenders, MD, PhD; Gert A. van Montfrans, MD, PhD; John M. Karemaker, PhD</i>	1329
Long-Term Survival of Dialysis Patients in the United States With Prosthetic Heart Valves: Should ACC/AHA Practice Guidelines on Valve Selection Be Modified? <i>Charles A. Herzog, MD; Jennie Z. Ma, PhD; Allan J. Collins, MD</i>	1336
Natural History of Brugada Syndrome: Insights for Risk Stratification and Management <i>Silvia G. Priori, MD, PhD; Carlo Napolitano, MD, PhD; Maurizio Gasparini, MD; Carlo Pappone, MD; Paolo Della Bella, MD; Umberto Giordano, MD; Raffaella Bloise, MD; Carla Giustetto, MD; Roberto De Nardis, MD; Massimiliano Grillo, MD; Elena Ronchetti, PhD; Giovanna Faggiano, MD; Janni Nastoli, BS</i>	1342
BG9719 (CVT-124), an A₁ Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy <i>Stephen S. Gottlieb, MD; D. Craig Brater, MD; Ignatius Thomas, MD; Edward Havranek, MD; Robert Bourge, MD; Steven Goldman, MD; Farere Dyer, MD; Miguel Gomez, MD; Donald Bennett, MD; Barry Ticho, MD; Evan Beckman, MD; William T. Abraham, MD</i>	1348
Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease <i>Carmine Zoccali, MD; Francesca Mallamaci, MD; Saverio Parlongo, MD; Sebastiano Cutrupi; Francesco Antonio Benedetto, MD; Giovanni Tripepi; Graziella Bonanno, MD; Francesco Rapisarda, MD; Pasquale Fatuzzo, MD; Giuseppe Seminara, MD; Alessandro Cateliotti; Benedetta Stancanelli, MD; Lorenzo Salvatore Malatino, MD</i>	1354

Basic Science Reports

Maternal Hypercholesterolemia During Pregnancy Promotes Early Atherogenesis in LDL Receptor-Deficient Mice and Alters Aortic Gene Expression Determined by Microarray <i>Claudio Napoli, MD; Filomena de Nigris, PhD; John S. Welch, BS; Federico B. Calara, PhD; Robert O. Stuart, MD; Christopher K. Glass, MD; Wulf Palinski, MD</i>	1360
Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene <i>Tommaso Simoncini, MD, PhD; Andrea R. Genazzani, MD, PhD; James K. Liao, MD</i>	1368
Propranolol Prevents the Development of Heart Failure by Restoring FKBP12.6-Mediated Stabilization of Ryanodine Receptor <i>Masahiro Doi, MD; Masafumi Yano, MD, PhD; Shigeki Kobayashi, MD, PhD; Masateru Kohno, MD; Takahiro Tokuhisa, MD; Shinichi Okuda, MD; Masae Suetsugu, BS; Yuhji Hisamatsu, MD, PhD; Tomoko Ohkusa, MD, PhD; Michihiro Kohno, MD, PhD; Masunori Matsuzaki, MD, PhD</i>	1374

Effects of Cariporide and Losartan on Hypertrophy, Calcium Transients, Contractility, and Gene Expression in Congestive Heart Failure
Jan P. Loennechen, MD; Ulrik Wisløff, MSc, PhD; Geir Falek, MD, PhD; Øyvind Ellingsen, MD, PhD 1380

Clinical Cardiology: New Frontiers

New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I: Diagnosis, Prognosis, and Measurements of Diastolic Function
Michael R. Zile, MD; Dirk L. Brutsaert, MD 1387

Images in Cardiovascular Medicine

Left Ventricular Involvement in Arrhythmogenic Right Ventricular Cardiomyopathy
J.A. McCrohon, MD, PhD; A.S. John, MD; C.H. Lorenz, PhD; S.W. Davies, MD; D.J. Pennell, MD 1394

Annotated Table of Contents A10
Classified Advertising B1

The cover figure is from the article in this issue by McCrohon et al. Figure 2. T1-weighted turbo spin-echo images before the application of a fat saturation pulse over the region of interest. The arrows point to areas of fatty infiltration of the anterior and inferior myocardium from the epicardial surface. Fatty infiltration is confirmed by the nulling of these areas (black regions) using a fat saturation prepulse in the same plane. The RV free wall shows diffuse high signal consistent with fat (C). See p 1394.

Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts

Donald S. Baim, MD; Dennis Wahr, MD; Barry George, MD; Martin B. Leon, MD; Joel Greenberg, MD; Donald E. Cutlip, MD; Unsal Kaya, MS; Jeffrey J. Popma, MD; Kalon K.L. Ho, MD, MSc; Richard E. Kuntz, MD, MSc; on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators

Background—Stents provide effective treatment for stenotic saphenous venous aorto-coronary bypass grafts, but their placement carries a 20% incidence of procedure-related complications, which potentially are related to the distal embolization of atherosclerotic debris. We report the first multicenter randomized trial to evaluate use of a distal embolic protection device during stenting of such lesions.

Methods and Results—Of 801 eligible patients, 406 were randomly assigned to stent placement over the shaft of the distal protection device, and 395 were assigned to stent placement over a conventional 0.014-inch angioplasty guidewire (control group). The primary end point—a composite of death, myocardial infarction, emergency bypass, or target lesion revascularization by 30 days—was observed in 65 patients (16.5%) assigned to the control group and 39 patients (9.6%) assigned to the embolic protection device ($P=0.004$). This 42% relative reduction in major adverse cardiac events was driven by myocardial infarction (8.6% versus 14.7%, $P=0.008$) and “no-reflow” phenomenon (3% versus 9%, $P=0.02$). Clinical benefit was seen even when platelet glycoprotein IIb/IIIa receptor blockers were administered (61% of patients), with composite end points occurring in 10.7% of protection device patients versus 19.4% of control patients ($P=0.008$).

Conclusions—Use of this distal protection device during stenting of stenotic venous grafts was associated with a highly significant reduction in major adverse events compared with stenting over a conventional angioplasty guidewire. This demonstrates the importance of distal embolization in causing major adverse cardiac events and the value of embolic protection devices in preventing such complications. (*Circulation*. 2002;105:1285-1290.)

Key Words: embolism ■ grafting ■ stenosis ■ angioplasty ■ stents

Catheter-based intervention in saphenous venous aorto-coronary bypass grafts carries a significant ($\approx 20\%$) risk of a major adverse clinical event (MACE) (predominantly myocardial infarction) or reduced antegrade flow (the no-reflow phenomenon).¹ Several mechanisms have been offered, including spasm of the distal microcirculation, platelet clumping, and most recently, the distal embolization of pieces of friable lipid-rich plaque.² Preliminary work with the PercuSurge GuardWire—a device for transient distal balloon occlusion during angioplasty or stent placement that allows recovery of any liberated plaque by aspiration before restoration of antegrade flow—has demonstrated consistent recovery of plaque constituents (cholesterol crystals, foam cells, fibrous plaque) that otherwise would have embolized into the myocardial bed.³ This initial experience has also suggested a

reduced incidence of myocardial infarction ($<6\%$) compared with the 20% historical rate of infarction seen without such distal protection.⁴ The Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) trial was an 801-patient US multicenter study in which patients undergoing saphenous vein graft intervention were randomized to undergo either stenting with a conventional guidewire or stenting with the GuardWire distal protection device. The SAFER trial was the pivotal trial that led to US Food and Drug Administration approval in August 2001.

Methods

The primary objective of Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) trial was to compare the 30-day clinical outcome after saphenous vein graft stenting plus GuardWire

Received December 28, 2001; revision received January 31, 2002; accepted January 31, 2002.

From the Division of Cardiovascular Diseases, Brigham and Women's Hospital, Boston Mass (D.S.B., J.J.P., R.E.K.); Harvard Clinical Research Institute, Boston, Mass (D.S.B., D.E.C., U.K., K.K.L.H., R.E.K.); Riverside Hospital, Columbus, Ohio (B.G.); St Joseph's Mercy Hospital, Ann Arbor, Mich (D.W.); Cardiovascular Research Foundation, Lenox Hill Hospital, New York, NY (M.B.L.); Florida Hospital, Orlando, Fla (J.G.); and Beth Israel Deaconess Medical Center, Boston, Mass (D.E.C., K.K.L.H.).

Dr Leon served as a consultant to PercuSurge Corporation during the trial.

This article originally appeared Online on February 25, 2002 (*Circulation*. 2002;105:r13-r18).

Correspondence to Donald S. Baim, MD, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail dbaim@partners.org

© 2002 American Heart Association, Inc.

Circulation is available at <http://www.circulationaha.org>

DOI: 10.1161/01.CIR.0000012783.63093.0C

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.